News

Angelman gene therapy is made for preclinical-clinical translation

Because antisense oligonucleotide (ASO) therapies target specific genetic sequences, differences across mammals make it challenging to translate potential Angelman ASO-based therapies from preclinical models to the clinic. GTX-102, an investigational ASO therapy for Angelman syndrome, was specifically designed to be effective in patients and relevant animal models, however.

UBE3A protein lacking in patients needed early for brain circuitry

The UBE3A protein is needed shortly after birth for the proper development of the dorsomedial striatum, part of a brain region called the basal ganglia, a mouse study suggests. Findings shed new light on the neurological disruptions that give rise to Angelman syndrome and its symptoms, a disease caused by mutations that…

Sleep duration, quality improves with behavioral intervention

A tailored behavioral intervention program led to longer sleep time, better sleep habits, and improved quality of life in children with Angelman syndrome, a Dutch study reports. The findings suggest “behavioral intervention has a positive and persistent effect on sleep problems in children with AS [Angelman symdrome],” the researchers…

Severe seizure events found to be common in Angelman patients

Severe seizure events known as status epilepticus are common in people with Angelman syndrome, especially during childhood, a new review study found. Researchers noted that status epilepticus often causes subtle symptoms that may be overlooked by caregivers and clinicians, highlighting the importance of correctly identifying and promptly treating these…

International Angelman Day to be observed on Feb. 15

Organizations around the world will come together Feb. 15 to observe International Angelman Day (IAD), a global effort to raise awareness, honor those living with the rare neurological disease and commemorate those who have passed away. The annual initiative also seeks to encourage fundraising and support research for…